目的评价美沙拉嗪联合酪酸梭菌肠球菌三联活菌片治疗溃疡性结肠炎(UC)的疗效.方法将确诊的54例轻、中度UC患者分为两组，治疗组(n=27)口服美沙拉嗪联合酪酸梭菌肠球菌三联活菌片；对照组(n=27)口服美沙拉嗪，治疗8周后评价治疗效果.结果8周后治疗组有效率92.5%，明显高于对照组的.96%(P <0.05)，且未见明显不良反应.结论美沙拉嗪联合酪酸梭菌肠球菌三联活菌片治疗UC可提高治疗效果.%Objective To evaluate the clinical efficacy of mesalazine combined with triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus for ulcerative colitis. Methods 54 patients with mild and moderate ulcerative colitis were randomly divided into two groups treatment. Group 27 patients orally took mesalazine combined with triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus. Other 27 patients orally took mesalazine. After eight weeks of treatment, the clinical effect and changes were observed colonoscopically. Results After eight weeks of treatment, the complete remission rate in treatment group 92.5% was significantly higher than in control group 62.96% with no obvious ADR(P <0.05). Conclusion The combined therapy with mesalazine and triple live bacterial agent of clostridium butyricum streptococcus faecalis bacillus mesentericus for ulcerative colitis could significantly raise the therapeutic efficacy.
展开▼
